References
- BaumgartDCSandbornWJInflammatory bowel disease: clinical aspects and established and evolving therapiesLancet200736995731641165717499606
- National Institutes of Health [homepage on the Internet]Ulcerative colitisNIH2010 [updated May 24, 2017]. Available from: https://medlineplus.gov/ulcerativecolitis.htmlAccessed July 20, 2017
- National Institute for Health and Care Excellence [homepage on the Internet]Clinical Guidelines CG166: Ulcerative ColitisNICE2010 Available from: https://www.nice.org.uk/guidance/cg166/chapter/introductionAccessed July 20, 2017
- RubinDTDubinskyMCPanaccioneRSiegelCABinionDGKaneSVHopperJThe impact of ulcerative colitis on patients’ lives compared to other chronic diseases: a patient surveyDig Dis Sci20105541044105220155319
- CohenRDYuAPWuEQXieJMulaniPMChaoJSystematic review: the costs of ulcerative colitis in Western countriesAliment Pharmacol Ther201031769370720064142
- KornbluthASacharDBPractice Parameters Committee of the American College of GastroenterologyUlcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice ParametersAm J Gastroenterol2010105350152320068560
- FeaganBGRutgeertsPSandsBEVedolizumab as induction and maintenance therapy for ulcerative colitisN Engl J Med2013369869971023964932
- SandbornWSandsBRutgeertsPSustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trialJ Crohns Colitis20137S138S139
- WilsonMKerriganMSmythMChevrou-SeveracHBergmanASelbyRCost-effectiveness of vedolizumab compared with conventional therapy for the treatment of moderately-to-severely active ulcerative colitis in the United KingdomUEG Journal20153Suppl 1A608
- TsaiHHPunekarYSMorrisJFortunPA model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitisAliment Pharmacol Ther200828101230123918729845
- PunekarYSHawkinsNCost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitisEur J Health Econ2010111677619844750
- WilsonMRBergmanAChevrou-SeveracHSelbyRSmythMKerriganMCCost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United KingdomEur J Health Econ Epub201738
- Office for National Statistics [homepage on the Internet]Death registrations summary tables, England and Wales 2010ONS2011 Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathregistrationssumma-rytablesenglandandwalesreferencetablesAccessed August 07, 2017
- Royal College of PhysiciansNational clinical audit of biological therapies: UK inflammatory bowel disease (IBD) audit Available from: https://www.rcplondon.ac.uk/projects/outputs/national-clinical-audit-report-biological-therapies-adult-report-2013Accessed August 07, 2017
- British National Formulary6602014 [cited 2014 Dec]. Available from: http://www.bnf.org/bnf/go?bnf/current/
- Department of HealthNHS reference costs 2013 to 2014NHS2013 [updated March 9, 2015]. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014Accessed July 20, 2017
- BuchananJWordsworthSAhmadTManaging the long term care of inflammatory bowel disease patients: the cost to European health care providersJ Crohns Colitis20115430131621683300
- BryanSAndronisLHydeCConnockMFry-SmithAWangDInfliximab for the treatment of acute exacerbations of ulcerative colitisHealth Technol Assess201014Suppl 191520507798
- Personal Social Services Research UnitCurtisLUnit costs of health and social care 2014PSSRU2014 Available from: http://www.pssru.ac.uk/archive/pdf/uc/uc2014/full-with-covers.pdfAccessed July 20, 2017
- BrownREHuttonJBurrellACost effectiveness of treatment options in advanced breast cancer in the UKPharmacoeconomics200119111091110211735676
- PorcoTCLewisBMarseilleEGrinsdaleJFloodJMRoyceSECost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrantsBMC Public Health2006615716784541
- HornbergerJReyesCLubeckDValenteNEconomic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphomaLeuk Lymphoma200849222723618231908
- BeusterienKMDaviesJLeachMMeiklejohnDGrinspanJLO’TooleABramham-JonesSPopulation preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility studyHealth Qual Life Outcomes201085020482804
- BeusterienKMSzaboSMKotapatiSSocietal preference values for advanced melanoma health states in the United Kingdom and AustraliaBr J Cancer2009101338738919603025
- European Crohn’s and Colitis Organisation [homepage on the Internet]SchreiberSDignassAPeyrin-BirouletLHatherGDemuthDKhalidJMLoftusEVReal world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis. Digestive Disease Week (DDW) 2017 Poster 1700. Available from: https://www.ecco-ibd.eu/publications/congress-abstracts/abstracts-2017/item/p466-real-world-effectiveness-of-vedolizumab-over-one-year-in-inflammatory-bowel-disease-a-meta-analysis-2.htmlAccessed August 07, 2017